International Assets Investment Management LLC Acquires New Stake in Axonics, Inc. (NASDAQ:AXNX)

International Assets Investment Management LLC purchased a new position in Axonics, Inc. (NASDAQ:AXNX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,131 shares of the company's stock, valued at approximately $817,000.

Other institutional investors have also made changes to their positions in the company. RiverPark Advisors LLC purchased a new stake in shares of Axonics during the 3rd quarter worth about $58,000. C M Bidwell & Associates Ltd. grew its position in Axonics by 108.2% in the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company's stock worth $71,000 after acquiring an additional 660 shares in the last quarter. Covestor Ltd increased its stake in shares of Axonics by 40.8% during the 3rd quarter. Covestor Ltd now owns 3,143 shares of the company's stock worth $176,000 after purchasing an additional 911 shares during the last quarter. Janney Capital Management LLC bought a new position in shares of Axonics during the 3rd quarter valued at $214,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Axonics in the 3rd quarter valued at $230,000. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AXNX has been the topic of several analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Axonics in a research report on Monday, May 6th. Royal Bank of Canada reissued a "sector perform" rating and set a $71.00 price objective on shares of Axonics in a report on Thursday, February 29th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $70.73.

Axonics Stock Down 0.2 %

NASDAQ:AXNX traded down $0.12 during trading hours on Friday, reaching $67.55. The company had a trading volume of 236,660 shares, compared to its average volume of 461,148. Axonics, Inc. has a one year low of $47.59 and a one year high of $69.68. The firm has a market capitalization of $3.45 billion, a PE ratio of -211.09 and a beta of 0.60. The stock has a 50-day moving average of $67.72 and a two-hundred day moving average of $64.37.

Axonics (NASDAQ:AXNX - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.32). Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The company had revenue of $91.41 million during the quarter, compared to the consensus estimate of $89.79 million. During the same period in the prior year, the firm posted ($0.19) earnings per share. The company's revenue was up 29.4% on a year-over-year basis. As a group, sell-side analysts expect that Axonics, Inc. will post 0.13 earnings per share for the current year.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.